Reimagining RNA medicine

Oct 01, 2026

Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD

Sep 30, 2026

Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development

Sep 23, 2026

Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity

Sep 22, 2026

Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer

Sep 03, 2026

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

Aug 10, 2026

Wave Life Sciences Announces Completion of Redomiciliation to Delaware

Aug 05, 2026

Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware

Aug 04, 2026

Wave Life Sciences to Present at Upcoming Investor Conferences

Jul 30, 2026

Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Jul 23, 2026

Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026